Table 1.
Included Studies, Study Characteristics, and Cancer Patient numbers.
| Author, Year | Patient Numbers | Study Characteristics |
|---|---|---|
| Awad et al., 2020 [9] | 14 CP/111 MTs * (12.6% **) | MT files, mortality predictors study, any history of cancer |
| Cho et al., 2020 [10] | 27 CP/378 MTs (7.2%) | MT files, active CP vs. NCP *3 |
| Ciolli et al., 2021 [11] | 14 CP/305 MTs (4.5%) | MT files, active CP vs. NCP (+/− history of cancer) |
| Jeon et al., 2021 [19] | 62 CRS | MT files, MT technique comparison in CRS |
| Joshi et al., 2022 [6] | 19 CP/95 matched NCP | MT files, 1:5 propensity-matched analysis |
| Jung et al., 2018 [12] | 19 CRS/329 MTs (5.7%) | MT files, CRS vs. non-CRS |
| Lee et al., 2019 [13] | 26 CP/253 MTs (10.2%) | MT files, active CP vs. NCP, history of cancer excluded |
| Lee et al., 2021 [14] | 34 CRS/341 MTs (9.9%) | MT files, CRS vs. non-CRS |
| Mattingly et al., 2022 [8] | 25 CP/284 MTs (8.8%) | MT files, active CP vs. NCP |
| Merlino et al., 2021 [15] | 21 CP *4/173 MTs (12.1%) | MT files, active CP vs. NCP vs. remote CP |
| Murthy et al., 2013 [20] | 193CP/6766 IVT+MTs (2.8%) | IVT files, ICD codes, IVT+MT, active CP vs. NCP |
| Oki et al., 2020 [7] | 12 CP/124 MTs (9.6%) | MT files, active CP vs. NCP |
| Ozaki et al., 2021 [16] | 19 CP/300 MTs (6.3%) | MT files, active CP vs. NCP |
| Pana et al., 2021 [21] | 1330 CP/34,420 MTs (3.8%) | IS files, ICD codes, active CP +/− metastasis vs. NCP |
| Rinaldo et al., 2019 [22] | 857 CP/17,268 MTs (4.9%) | IS files, ICD codes, active CP vs. NCP |
| Sallustio et al., 2019 [17] | 24 CP/24 matched NCP | MT files, 1:1 matched analysis |
| Verschoof et al., 2022 [23] | 124 CP/2583 MTs (4.8%) | MR CLEAN Registry, active CP vs. NCP |
| Yoo et al., 2021 [18] | 42 CP *4/685 MTs (6.1%) | MT files, active CP vs. NCP vs. remote CP |
* MTs: all MT patients. ** Data was available for 111 out of 134 MTs, a percentage possibly not representative of the CP fraction. *3 Non-cancer patients. *4 Only patients with active cancer.